- Disease: Acute COVID-19
- Study type: Observational Cohort Study, Treatment
- Study type descriptors: Prospective, Single centre
- Objective: To assess the efficacy of early combination treatment with one antiviral and a monoclonal antibody, presumably active against the circulating SARS-CoV-2 variant, in non-hospitalized immunocompromised outpatients with mild-to-moderate COVID-19
- Number of participants enrolled: 52
- Study enrolling from to
- Study includes follow-up for 3 months
Study Data
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Fragile population
- Hospital
- Emergency department
- SARS-CoV-2
- Pharmacological intervention
- Antivirals
- Monoclonal antibodies
- Remdesivir
- Nirmatrelvir/Ritonavir
- Sotrovimab
External Links
Other information
Funders/Sponsors:
- NextGenerationeU-MUR PNRR extended Partnership initiative on emerging infectious Diseases
The information was provided with the aid of the study investigators
If you would like to contact the Principal Investigator of the study please email: ccb@ateneo.univr.it
The data is updated up to